ResearcherSecond Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Lei Dong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5495-7121; OpenAlex author ID A5038079033. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 2

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hong Li · 1 shared paper, 2022 · strength 0.15
- Paper SQLE facilitates the pancreatic cancer progression via the lncRNA-TTN-AS1/miR-133b/SQLE axis. DOI 10.1111/jcmm.17347 ↗
Jing Zhang · 1 shared paper, 2022 · strength 0.15
- Paper SQLE facilitates the pancreatic cancer progression via the lncRNA-TTN-AS1/miR-133b/SQLE axis. DOI 10.1111/jcmm.17347 ↗
Shuhui Wang · 1 shared paper, 2022 · strength 0.15
- Paper SQLE facilitates the pancreatic cancer progression via the lncRNA-TTN-AS1/miR-133b/SQLE axis. DOI 10.1111/jcmm.17347 ↗
Ting Wang · 1 shared paper, 2022 · strength 0.15
- Paper SQLE facilitates the pancreatic cancer progression via the lncRNA-TTN-AS1/miR-133b/SQLE axis. DOI 10.1111/jcmm.17347 ↗
Jing Li · 1 shared paper, 2016 · strength 0.08
- Paper Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. DOI 10.3892/or.2016.4924 ↗
Yan Wang · 1 shared paper, 2016 · strength 0.08
- Paper Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. DOI 10.3892/or.2016.4924 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.